Abstract: Disclosed are pharmaceutical compositions comprising a CIRP inhibitor. A method of treating a subject suffering from an inflammatory condition comprising administering to said subject a CIRP inhibitor is also described herein.

Abstract: Compounds of Formula (I), pharmaceutical compositions comprising compounds of Formulae (I a) or (VII) and a method of treating a subject with an inflammatory cytokine-mediated disorder comprising administering to the subject a compound of Formulae (I a) or (VIIa). The variables of Formulae (I), (I a), (VII) and (VII a) are described herein.

Abstract: Small molecule compounds are provided for treating lupus as are methods of treating lupus using these compounds.

Abstract: Methods are provided for treating pathologies associated with hypoxia with an MIF inhibitor. Methods are also provided for treating a subject having, or at risk for pulmonary hypertension, with an MIF inhibitor. Methods are also provided for treating a subject having, or at risk from, a CNS disorder associated with hypoxia, with an MIF inhibitor. Methods are also provided of treating severe chronic lung disease, hypoxia-induced right ventricular hypertrophy or hypoxia-induced pulmonary vascular remodeling with an MIF inhibitor. Methods of diagnosing a subject with pulmonary hypertension are also provided.

Abstract: Provided are various compounds of Formula (I): Also provided are pharmaceutical compositions comprising the above compounds. Additionally, methods of inhibiting macrophage migration inhibitory factor (MIF) activity in a mammal are provided, as are methods of treating or preventing inflammation in a mammal. Further provided are methods of treating a mammal having sepsis, septicemia, and/or endotoxic shock. Also provided are methods of treating a mammal having an autoimmune disease, and methods of treating a mammal having a tumor.

Abstract: Disclosed is a method of reducing bleed time in a subject by activation of the cholinergic anti-inflammatory pathway in said subject. The cholinergic anti-inflammatory pathway can be activated by direct or indirect stimulation of the vagus nerve. The cholinergic anti-inflammatory pathway can also be activated by administering an effective amount of cholinergic agonist or acetylcholinesterase inhibitor to the subject.

Abstract: A flexible spirally-rolled polymer microtube for in vivo monitoring and treatment of brain injuries; the tube integrally comprising one or more microsensors and one or more microchannels, wherein the microsensors monitor one or more parameters and the microchannels are capable of delivering substances to the brain, removing substances from the brain, or both.

Abstract: The present invention is directed to a method of treating a subject at risk for or having a condition mediated by an inflammatory cytokine cascade comprising administering to the subject an amount of a GAPDH inhibitor effective to treat the subject at risk for or having a condition mediated by an inflammatory cytokine cascade.

Abstract: Disclosed are pharmaceutical compositions comprising a CIRP inhibitor. A method of treating a subject suffering from an inflammatory condition comprising administering to said subject a CIRP inhibitor is also described herein.

Abstract: Methods of treating a mammal at risk for ischemia-reperfusion injury are provided. The methods comprise administering an adrenomedullin binding protein-1 (AMBP-1) to the mammal in sufficient amount to reduce the injury. Also provided are methods of treating a mammal at risk for ischemia-reperfusion injury to the bowel. The methods comprise administering adrenomedullin to the mammal in sufficient amount to reduce the injury.

Abstract: A privacy curtain assembly includes a main curtain portion. The main curtain portion includes a first side, a second side, and oppositely disposed leading edges located between the first and second sides. The privacy curtain assembly also includes at least one cleanable, wipable panel that is permanently affixed to one of the leading edges of the main curtain portion. The at least one panel is configured to be cleaned while permanently affixed to the main curtain portion.

Abstract: A flexible spirally-rolled polymer microtube for in vivo monitoring and treatment of brain injuries; the tube integrally comprising one or more microsensors and one or more microchannels, wherein the microsensors monitor one or more parameters and the microchannels are capable of delivering substances to the brain, removing substances from the brain, or both.

Abstract: Provided are various compounds of Formula I (I). Also provided are various compounds of Formula II (II). Also provided are pharmaceutical compositions comprising the above compounds. Additionally, methods of inhibiting macrophage migration inhibitory factor (MIF) activity in a mammal are provided, as are methods of treating or preventing inflammation in a mammal. Further provided are methods of treating a mammal having sepsis, septicemia, and/or endotoxic shock. Also provided are methods of treating a mammal having an autoimmune disease, and methods of treating a mammal having a tumor.

Abstract: The present invention is directed to a method of treating systemic lupus erythematosus (SLE) in a subject comprising administering to the subject an amount of an HIV protease inhibitor effective to treat SLE. The present invention is also directed to a pharmaceutical product comprising an HIV protease inhibitor formulated in a pharmaceutically acceptable carrier, and a package insert providing instructions for the administration of the HIV protease inhibitor for the treatment of SLE. In addition, the present invention is directed to the use of an HIV protease inhibitor for the preparation of a medicament for the treatment of SLE.

Abstract: The present invention provides a method for distinguishing benign human papilloma virus (HPV)-infected tissue from HPV-related lesions that have undergone malignant transformation. In one embodiment, the invention comprises a simple histochemical staining method and details a novel process for examining HPV-infected cells by determining susceptibility to enzymatic DNA digestion. Residual virion-associated DNA is seen only in benign HPV-infected lesions, while absence of residual DNA is seen with malignant transformation. In another embodiment, the invention comprises immunohistochemical assay methods for examining HPV-infected cells, utilizing antibodies to HPV L1 proteins. These methods can be used to predict biologic behavior of HPV-infected lesions. The invention can improve current cervical cancer screening programs, and improve clinical management of patients by defining malignant potential of HPV-infected tissue more accurately.

Abstract: An antibody or an antigen binding fragment thereof which binds to mammalian ?7 subunit of a nicotinic acetylcholine receptor or its functional variant and which is an agonist of said receptor or variant. Pharmaceutical compositions comprising same. A method of treating a subject suffering from an inflammatory condition comprising administering to said subject an antibody or an antigen-binding fragment as described herein.

Abstract: Provided are methods of attenuating release of a proinflammatory cytokine from a mammalian cell. Also provided are methods of inhibiting or treating an inflammatory cytokine cascade in a mammal. Further provided are methods of treating a mammal at risk for or undergoing sepsis, septicemia, and/or endotoxic shock. Additionally provided are methods of attenuating NO release from a mammalian cell. Also provided are methods of attenuating NO production in a mammal at risk for, or having, a disorder mediated by excessive NO production.

Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise a vertebrate HMGB A box, and an antibody preparation that specifically binds to a vertebrate HMGB B box. The methods comprise treating a cell or a patient with sufficient amounts of the composition to inhibit the release of the proinflammatory cytokine, or to inhibit the inflammatory cytokine cascade.

Abstract: Provided are various compounds of Formula I (I). Also provided are various compounds of Formula II (II). Also provided are pharmaceutical compositions comprising the above compounds. Additionally, methods of inhibiting macrophage migration inhibitory factor (MIF) activity in a mammal are provided, as are methods of treating or preventing inflammation in a mammal. Further provided are methods of treating a mammal having sepsis, septicemia, and/or endotoxic shock. Also provided are methods of treating a mammal having an autoimmune disease, and methods of treating a mammal having a tumor.

Abstract: Small molecule compounds are provided for treating lupus as are methods of treating lupus using these compounds.